（记者 王晓波） 每经AI快讯，有投资者在投资者互动平台提问：东华在海南投入这么多业务板块，肯定会给公司带来 很大的业务营收，公司如何抓住机遇？ 东华软件（002065.SZ）1月6日在投资者互动平台表示，公司积极响应国家战略号召，在海南自贸港建 设进程中提前布局，于封关前持续投入人力、物力、财力，设立了子公司并建设研发中心，以支持在琼 业务的长远发展。研发中心未来将覆盖东南亚市场，在越南地区，为其提供技术支持与服务。目前，在 东盟地区的业务推广已取得初步成效，覆盖越南、马来西亚、印尼等国。公司的医疗软件产品已成功落 地并实现多个订单突破。此外，公司包括在电力、铁路和金融领域的相关项目也正在稳步推进和交流 中。 ...

Group 1 - The core viewpoint of the news is that Weining Health has experienced a decline in stock performance and financial metrics, indicating potential challenges in its business operations [1][2]. - As of December 29, Weining Health's stock price fell by 0.80%, with a trading volume of 400 million yuan. The net financing buy was -7.38 million yuan, indicating more repayments than new purchases [1]. - The financing balance of Weining Health reached 1.363 billion yuan, accounting for 7.09% of its market capitalization, which is above the 80th percentile of the past year [1]. Group 2 - For the period from January to September 2025, Weining Health reported a revenue of 1.296 billion yuan, a year-on-year decrease of 32.27%, and a net profit attributable to shareholders of -241 million yuan, a significant decline of 256.10% [2]. - The company has distributed a total of 455 million yuan in dividends since its A-share listing, with 97.23 million yuan distributed over the past three years [3]. - As of September 30, 2025, the number of Weining Health's shareholders decreased to 111,000, while the average circulating shares per person increased to 17,249 shares [2][3].

Core Viewpoint - Weining Health's stock has shown fluctuations in recent trading sessions, with a year-to-date increase of 22.74% but a decline over the last 60 days of 12.91% [1] Financial Performance - For the period from January to September 2025, Weining Health reported a revenue of 1.296 billion yuan, a year-on-year decrease of 32.27%, and a net profit attributable to shareholders of -241 million yuan, reflecting a significant decline of 256.10% [2] - Cumulative cash dividends since the A-share listing amount to 455 million yuan, with 97.226 million yuan distributed over the last three years [3] Shareholder Structure - As of November 20, 2025, the number of Weining Health's shareholders decreased by 1.51% to 112,400, while the average circulating shares per person increased by 1.53% to 17,039 shares [2] - The top ten circulating shareholders include notable funds such as Huabao Zhongzheng Medical ETF and Yifangda Growth Mixed A, with some shareholders reducing their stakes [3] Stock Market Activity - On December 1, Weining Health's stock price reached 8.77 yuan per share, with a trading volume of 312 million yuan and a turnover rate of 1.89% [1] - The stock has appeared on the "Dragon and Tiger List" twice this year, with the most recent occurrence on February 7 [1] Business Overview - Weining Health, established on April 7, 2004, and listed on August 18, 2011, specializes in medical software development, sales, and technical services, providing comprehensive solutions for the healthcare industry's information technology needs [1] - The company's revenue composition includes 84.65% from software and services, 7.89% from hardware sales, and 7.46% from internet healthcare [1] Industry Classification - Weining Health is classified under the Shenwan industry category of Computer-Software Development-Vertical Application Software, and is associated with concepts such as AI models, domestic software, Alibaba Cloud, and DRG concepts [1]

11月24日，卫宁健康涨5.23%，截至发稿，报8.45元/股，成交4.95亿元，换手率3.13%，总市值187.14亿 元。 资料显示，卫宁健康科技集团股份有限公司位于上海市静安区寿阳路99弄9号卫宁健康大厦，成立日期 2004年4月7日，上市日期2011年8月18日，公司主营业务涉及医疗软件研究开发、销售与技术服务业务, 并为医疗卫生行业信息化提供整体解决方案。主营业务收入构成为：软件及服务84.65%，硬件销售 7.89%，互联网医疗健康7.46%，其他0.00%。 前海联合泳隽混合A（004693）成立日期2018年1月29日，最新规模92.72万。今年以来收益5.45%，同 类排名6341/8209；近一年收益1.74%，同类排名7392/8129；成立以来收益59.16%。 前海联合泳隽混合A（004693）基金经理为张永任。 截至发稿，张永任累计任职时间5年198天，现任基金资产总规模1.64亿元，任职期间最佳基金回报 47.46%， 任职期间最差基金回报-23.73%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标 ...

Core Viewpoint - The stock of Weining Health has shown fluctuations in price and trading volume, with a notable increase of 2.24% on November 24, reaching 8.21 CNY per share, and a total market capitalization of 18.182 billion CNY [1] Financial Performance - For the period from January to September 2025, Weining Health reported a revenue of 1.296 billion CNY, reflecting a year-on-year decrease of 32.27%. The net profit attributable to shareholders was -241 million CNY, a significant decline of 256.10% compared to the previous year [2] - The company has distributed a total of 455 million CNY in dividends since its A-share listing, with 97.226 million CNY distributed over the last three years [3] Stock Market Activity - As of November 24, 2023, Weining Health's stock has increased by 14.91% year-to-date, with a recent 5-day increase of 1.48%, a 20-day decline of 6.39%, and a 60-day decline of 24.82% [1] - The company has appeared on the "龙虎榜" (a list of stocks with significant trading activity) twice this year, with the latest appearance on February 7 [1] Shareholder Information - As of October 31, 2023, Weining Health had 114,100 shareholders, an increase of 0.47% from the previous period. The average number of circulating shares per shareholder was 16,781, a decrease of 0.46% [2] - The top ten circulating shareholders include notable funds such as Huabao Zhongzheng Medical ETF and Yifangda Growth ETF, with some shareholders reducing their holdings [3] Business Overview - Weining Health, established on April 7, 2004, and listed on August 18, 2011, specializes in the research, development, sales, and technical services of medical software, providing comprehensive solutions for the healthcare industry's information technology [1] - The company's revenue composition includes 84.65% from software and services, 7.89% from hardware sales, and 7.46% from internet healthcare [1] Industry Classification - Weining Health is classified under the computer software development industry, specifically in vertical application software, and is associated with concepts such as Alibaba Cloud, AI models, domestic software, DeepSeek, and Xinchuang [2]

Core Viewpoint - The stock of Weining Health has experienced a decline in recent trading sessions, with a notable drop of 11.55% over the last five days, despite a year-to-date increase of 13.65% [1][2] Group 1: Stock Performance - As of November 11, Weining Health's stock price was 8.12 CNY per share, with a market capitalization of 17.983 billion CNY [1] - The stock has seen a significant decline of 23.18% over the past 60 days [1] - The company has appeared on the trading leaderboard twice this year, with the most recent occurrence on February 7 [1] Group 2: Financial Performance - For the period from January to September 2025, Weining Health reported a revenue of 1.296 billion CNY, a decrease of 32.27% year-on-year [2] - The net profit attributable to shareholders was -241 million CNY, reflecting a substantial decline of 256.10% compared to the previous year [2] Group 3: Shareholder Information - As of October 31, the number of Weining Health's shareholders was 114,100, an increase of 0.47% from the previous period [2] - The average number of circulating shares per shareholder decreased by 0.46% to 16,781 shares [2] - The company has distributed a total of 455 million CNY in dividends since its A-share listing, with 97.226 million CNY distributed over the last three years [3] Group 4: Institutional Holdings - As of September 30, 2025, the top ten circulating shareholders included Huabao Zhongzheng Medical ETF, which held 50.0772 million shares, a decrease of 8.6961 million shares from the previous period [3] - The E Fund Growth Mixed A fund entered the top ten shareholders with a holding of 16.891 million shares [3]

Core Viewpoint - The stock of Weining Health has shown a mixed performance in recent trading sessions, with a year-to-date increase of 25.82% but a decline in the last five, twenty, and sixty days [1][2]. Financial Performance - As of September 30, Weining Health reported a revenue of 839 million yuan for the first half of 2025, representing a year-on-year decrease of 31.43%. The net profit attributable to shareholders was -118 million yuan, a significant decline of 491.04% compared to the previous year [2]. - Cumulative cash dividends since the A-share listing amount to 455 million yuan, with 97.23 million yuan distributed over the last three years [3]. Shareholder Information - The number of shareholders as of September 30 is 117,300, a decrease of 0.45% from the previous period. The average number of tradable shares per person increased by 0.49% to 16,323 shares [2]. - As of June 30, 2025, the top ten circulating shareholders include Huabao Zhongzheng Medical ETF and E Fund Growth Enterprise ETF, with notable changes in their holdings [3]. Stock Market Activity - On October 15, Weining Health's stock price rose by 2.04% to 8.99 yuan per share, with a trading volume of approximately 99.64 million yuan and a turnover rate of 0.58%. The total market capitalization stands at 19.91 billion yuan [1]. - The stock has appeared on the "Dragon and Tiger List" twice this year, with the most recent occurrence on February 7 [1].

Core Viewpoint - The stock of Weining Health has experienced a decline in recent trading sessions, with a notable drop in both revenue and net profit for the first half of 2025, indicating potential challenges for the company moving forward [1][2]. Company Overview - Weining Health Technology Group Co., Ltd. is based in Shanghai and was established on April 7, 2004, with its listing date on August 18, 2011. The company specializes in the research, development, sales, and technical services of medical software, providing comprehensive solutions for the healthcare industry's information technology [1]. - The main revenue composition of the company includes software and services (84.65%), hardware sales (7.89%), and internet healthcare (7.46%) [1]. Financial Performance - As of September 30, Weining Health reported a revenue of 839 million yuan for the first half of 2025, representing a year-on-year decrease of 31.43%. The net profit attributable to the parent company was -118 million yuan, a significant decline of 491.04% compared to the previous year [2]. - The company has cumulatively distributed 455 million yuan in dividends since its A-share listing, with 97.23 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, Weining Health had 117,300 shareholders, a decrease of 0.45% from the previous period. The average number of circulating shares per shareholder increased by 0.49% to 16,323 shares [2]. - The top circulating shareholders include Huabao Zhongzheng Medical ETF, which holds 58.77 million shares, and Yifangda Growth Enterprise Board ETF, holding 45.26 million shares, with some changes in their holdings compared to the previous period [3].

Core Viewpoint - The stock of Weining Health has shown a significant increase in price this year, with a year-to-date rise of 31.42%, despite recent fluctuations in trading volume and net capital outflow [1][2]. Financial Performance - For the first half of 2025, Weining Health reported a revenue of 839 million yuan, representing a year-on-year decrease of 31.43%. The net profit attributable to shareholders was -118 million yuan, a significant decline of 491.04% compared to the previous year [2]. - Cumulatively, Weining Health has distributed 455 million yuan in dividends since its A-share listing, with 97.23 million yuan distributed over the last three years [3]. Shareholder Structure - As of September 19, 2025, the number of shareholders for Weining Health was 117,800, a decrease of 0.53% from the previous period. The average number of circulating shares per person increased by 0.53% to 16,244 shares [2]. - The top ten circulating shareholders include notable entities such as Huabao Zhongzheng Medical ETF and E Fund Growth Enterprise Board ETF, with changes in their holdings noted [3].

Core Viewpoint - Yingkang Life's stock price increased by 1.78% on September 30, with a trading volume of 124 million yuan, indicating positive market sentiment towards the company [1]. Financing Summary - On September 30, Yingkang Life had a financing buy-in amount of 13.63 million yuan and a financing repayment of 27.28 million yuan, resulting in a net financing outflow of 13.65 million yuan [1]. - As of September 30, the total financing and securities lending balance for Yingkang Life was 269 million yuan, which accounts for 3.67% of its market capitalization, indicating a high level of financing activity compared to the past year [1]. - The company had a securities lending repayment of 16,800 shares and a securities lending sell-out of 200 shares, with a sell-out amount of 2,284 yuan, reflecting low securities lending activity [1]. Company Overview - Yingkang Life Technology Co., Ltd. is located in Qingdao, Shandong Province, and was established on August 6, 1998, with its listing date on December 9, 2010 [2]. - The company's main business involves medical devices and medical services, with a focus on developing, producing, and selling advanced radiation therapy equipment and establishing a specialized cancer treatment service network [2]. - The revenue composition of Yingkang Life includes 77.47% from medical services and 22.53% from medical devices and consumables [2]. Financial Performance - For the first half of 2025, Yingkang Life reported a revenue of 843 million yuan, representing a year-on-year growth of 2.40%, and a net profit attributable to shareholders of 61.83 million yuan, which is a 12.82% increase compared to the previous year [2]. Dividend Information - Since its A-share listing, Yingkang Life has distributed a total of 29.48 million yuan in dividends, with no dividends paid in the last three years [3].